---

---

tags : Product-news   

save search

---

Endo Launches Ibuprofen-Famotidine Tablets, Generic Version of DUEXIS®
Published: 2024-03-26 (Crawled : 20:00) - biospace.com/
ENDPQ | $0.0006 -50.0% 3.4K |

n/a

| 700.0% | O: -40.0% H: 33.33% C: 0.0%
duexis

---

Takeda Announces Approval of ADZYNMA® Intravenous Injection 1500 (apadamtase alfa /cinaxadamtase alfa) in Japan for Patients with Congenital Thrombotic Thrombocytopenic Purpura (cTTP)
Published: 2024-03-26 (Crawled : 18:00) - biospace.com/
TAK | News | $13.24 0.61% 0.0% 1.3M |

Health Technology

| -7.07% | O: 1.84% H: 0.24% C: -0.14%
adzynma japan takeda approval injection

---

Protagonist Therapeutics Provides Update on VERIFY Patient Enrollment and Timing of Top-line Data
Published: 2024-03-26 (Crawled : 12:00) - biospace.com/
JNJ | News | $147.91 1.49% -0.03% 9.6M |

Health Technology

| -6.86% | O: 0.01% H: 0.0% C: 0.0%
PTGX | $25.61 1.55% 1.52% 450K |

Health Technology

| -9.57% | O: 1.9% H: 0.0% C: -1.48%
update therapeutics

---

BD Increases Domestic Production to Support U.S. Health Care Need for Syringes
Published: 2024-03-21 (Crawled : 12:00) - biospace.com/
BDX | $234.12 0.42% 0.0% 1.3M |

Health Technology

| -2.88% | O: 0.46% H: 1.26% C: 1.11%
health care

---

European Commission Approves Pfizer’s PREVENAR 20® to Help Protect Infants and Children Against Pneumococcal Disease
Published: 2024-03-13 (Crawled : 11:00) - biospace.com/
PFE A | $26.0 2.4% -0.15% 38M |

Health Technology

| -9.25% | O: 1.0% H: 1.41% C: -0.25%
disease pneumococcal children

---

Biocon Biologics Secures US Market Entry Date for Bmab 1200, a Proposed Biosimilar to Stelara®
Published: 2024-02-29 (Crawled : 17:00) - biospace.com/
JNJ | News | $147.91 1.49% -0.03% 9.6M |

Health Technology

| -10.02% | O: 0.56% H: 0.12% C: -0.38%
stelara biosimilar market

---

Therapeutic Solutions International Announces Landmark Finding Regarding Mechanism of Action of its JadiCell Stem Cell Product
Published: 2024-02-29 (Crawled : 15:00) - biospace.com/
TSOI | $0.0007 0.0% 33M |

Manufacturing

| -5.56% | O: 11.11% H: 0.0% C: -10.0%
international cell solutions

---

Datopotamab Deruxtecan Biologics License Application Accepted in the U.S. for Patients with Previously Treated Advanced Nonsquamous Non-Small Cell Lung Cancer
Published: 2024-02-19 (Crawled : 09:00) - biospace.com/
AZN | News | $68.56 0.29% 0.29% 4.7M |

Health Technology

| Email alert Add to watchlist
lung license cancer cell application advanced

---

InnoCare Announces First Prescription of Tafasitamab in Combination with Lenalidomide for Relapsed or Refractory Diffuse Large B-Cell Lymphoma Under Greater Bay Area’s Early Access Program
Published: 2024-01-22 (Crawled : 07:00) - biospace.com/
XNCR | $18.385 -2.98% -3.07% 830K |

Health Technology

| -2.9% | O: 0.56% H: 1.97% C: 1.37%
MOR | News | $17.96 -0.5% -0.5% 180K |

Health Technology

| 96.84% | O: 0.11% H: 1.96% C: -0.27%
first bay program

---

Oxford BioTherapeutics Announces First Patient Dosed with OBT076 in Phase 1b Trial in Adenoid Cystic Carcinomas of the Head and Neck
Published: 2024-01-18 (Crawled : 11:00) - biospace.com/
AGEN | $5.3 6.64% 6.23% 1.5M |

Health Technology

| 735.43% | O: 1.78% H: 0.88% C: -6.95%
obt076 first trial

---

Xenetic Biosciences, Inc. Enters into Research Agreement with the University of Virginia for the Advancement of its DNase-Based Oncology Platform
Published: 2024-01-17 (Crawled : 14:30) - biospace.com/
XBIO | $4.14 7.32% 770 |

Health Technology

| 5.46% | O: 0.0% H: 0.0% C: -4.37%
research agreement platform

---

LegoChem Biosciences Announces License Agreement for LCB84 Trop2-Targeted ADC
Published: 2023-12-26 (Crawled : 06:00) - biospace.com/
JNJ | News | $147.91 1.49% -0.03% 9.6M |

Health Technology

| -6.6% | O: -0.16% H: 0.0% C: 0.0%
lcb84 license agreement

---

Thermo Fisher Scientific Announces Launch of Innovative CorEvitas Pharmacovigilance Platform for Clinical Research Registries
Published: 2023-12-20 (Crawled : 14:00) - biospace.com/
TMO | News | $544.78 0.6% 0.0% 1.7M |

Health Technology

| 2.18% | O: 1.22% H: 0.85% C: -1.62%
research platform

---

Innate Pharma Announces Licensing of a Fourth Natural Killer Cell Engager in Oncology to Sanofi
Published: 2023-12-19 (Crawled : 08:00) - biospace.com/
NVO | News | $122.71 -0.03% 0.17% 5M |

Health Technology

| 25.81% | O: 0.91% H: 0.72% C: 0.11%
SNY | News | $46.32 2.05% 2.01% 3.3M |

Health Technology

| -6.07% | O: 0.45% H: 0.0% C: 0.0%
IPHA | $2.48 5.53% 5.24% 9.4K |

Health Technology

| -4.08% | O: 13.88% H: 0.0% C: -3.58%
pharma natural cell sanofi

---

Delaware Federal District Court Rules in Favor of Acadia Pharmaceuticals in NUPLAZID® (pimavanserin) Patent Litigation
Published: 2023-12-13 (Crawled : 20:00) - biospace.com/
ACAD | $16.82 -1.47% -1.49% 3.5M |

Health Technology

| -18.71% | O: 1.56% H: 34.6% C: 32.42%
nuplazid patent pharmaceuticals

---

Paratek Pharmaceuticals Announces Inclusion of Oral NUZYRA® in China’s National Reimbursement Drug List
Published: 2023-12-13 (Crawled : 15:30) - biospace.com/
ZLAB | $14.08 -0.99% -0.99% 470K |

Health Technology

| -49.35% | O: 4.67% H: 10.29% C: 6.86%
nuzyra drug pharmaceuticals

---

European Commission Approves Pfizer’s ELREXFIO® for Relapsed and Refractory Multiple Myeloma
Published: 2023-12-08 (Crawled : 21:00) - biospace.com/
PFE A | $26.0 2.4% -0.15% 38M |

Health Technology

| -11.21% | O: 0.07% H: 1.1% C: 0.45%
elrexfio

---

uniQure Announces FDA Clearance of Investigational New Drug Application for AMT-191 Gene Therapy for Fabry DiseasePatient enrollment expected to begin in first half of 2024
Published: 2023-11-29 (Crawled : 14:30) - biospace.com/
QURE | $4.68 -0.64% -0.64% 550K |

Health Technology

| -32.52% | O: 0.0% H: 4.58% C: -2.58%
amt-191 fda drug expected clearance application therapy

---

Novocure Announces Portfolio Prioritization and Strategic Restructuring Plan Focused on Near-term Growth Drivers and an Accelerated Path to Profitability
Published: 2023-11-28 (Crawled : 15:00) - biospace.com/
NVCR | $12.09 0.33% 0.33% 850K |

Health Technology

| 1.18% | O: 0.0% H: 3.78% C: 2.43%
growth

---

Masimo W1™ Medical Watch Receives FDA 510(k) Clearance for Over-the-Counter and Prescription Use
Published: 2023-11-17 (Crawled : 22:00) - biospace.com/
MASI | $134.77 -0.85% -0.85% 350K |

Health Technology

| 46.81% | O: 0.09% H: 1.29% C: 0.7%
fda clearance medical

---

Gainers vs Losers

67%

33%

Top 10 Gainers

AGBA | News | $1.26 215.0% 68.25% 130M |

Finance

EGOX | $0.0515 43.06% 30.1% 330M |

OLB 4 | $0.33 -14.95% 25.53% 840K |

Technology Services

NVFY | $2.77 31.28% 23.83% 33M |

Consumer Durables

ZCMD | $1.87 28.97% 22.46% 31M |

Commercial Services

RCON | $0.1112 13.01% 21.28% 1.7M |

Distribution Services

INSG | $3.03 25.21% 20.13% 330K |

Electronic Technology

GCTK | $0.8191 22.25% 18.2% 190K |

Manufacturing

WLGS | $0.59 18.0% 17.9% 2.3M |

ASNS | $0.828 21.75% 17.86% 18K |

---

Your saved searches

---